Competition looms as Sanofi vaccine gets FDA's first dengue approval in narrow population

FDA approved Sanofi's dengue fever vaccine Dengvaxia in a narrower population than the pharma had sought, reflecting an advisory panel's conclusions in March and leaving the door open to vaccines in Phase III testing to potentially reach broader populations.

Dengvaxia is the first FDA-approved vaccine to prevent dengue disease. The agency approved it only to prevent the disease in people ages 9-16 who have previously been

Read the full 651 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE